- Home
- BTM vs FBIO Comparison
BTM vs FBIO Comparison
Compare BTM & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTM | FBIO |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | 126 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.4M | 113.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BTM | FBIO |
|---|---|---|
| Price | $1.36 | $4.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.25 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 889.2K | 689.1K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $635,643,000.00 | $62,303,000.00 |
| Revenue This Year | $7.87 | $29.71 |
| Revenue Next Year | N/A | $49.34 |
| P/E Ratio | $4.76 | ★ N/A |
| Revenue Growth | ★ 8.61 | N/A |
| 52 Week Low | $0.93 | $1.33 |
| 52 Week High | $6.88 | $4.34 |
Technical Indicators
Market Signals| Indicator | BTM | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 77.20 |
| Support Level | $1.25 | $4.02 |
| Resistance Level | $1.35 | $4.34 |
| Average True Range (ATR) | 0.08 | 0.23 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 53.13 | 91.08 |
Price Performance
Historical ComparisonAbout BTM Bitcoin Depot Inc.
Bitcoin Depot Inc owns and operates the widest network of BTMs across North America where customers can buy and sell Bitcoin. Bitcoin Depot helps power the digital economy for users of cash. It has locations across the U.S. and Canada at, among others, the following types of retailers: Convenience Stores and Gas Station Chains, Pharmacies and Grocers and Mall Operators.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.